Ohmori, Tsukasa, et al. «CRISPR / Cas9 - mediated genome editing via postnatal administration of AAV vector cures
haemophilia B mice.»
Only about 4 % of people with
haemophilia B develop inhibitors to factor IX.
Factor IX — which people with
haemophilia B lack — lasts longer, 18 — 24 hours.
2011 Six people with clotting disorder
haemophilia B see a reduction in symptoms after gene therapy on liver cells.
When treated with replacement coagulation proteins, the dog naturally develops antibodies, or inhibitors, against the therapy — a problem that is also seen in some 5 % of humans with
haemophilia B.
Roughly 5 % of those with
haemophilia B fall into this category, and 30 % of those with haemophilia A (see page S12).